Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤$234.7 million cash as of September 30, 2026, supports runway into Q1 2029
- ➤TX2100 Phase 1a showed favorable safety, tolerability and pharmacokinetic results
- ➤FDA granted TX2100 Fast Track designation and cleared its Phase 1b IND
- ➤TX45 APEX Phase 2 topline results expected by end of January 2027
- ➤TX45 ALPINE Phase 2a dosed its first PH-ILD patient in October 2026
Expert Statements
Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic
“The favorable safety, tolerability and PK results from the single ascending-dose portion of our TX2100 Phase 1a trial in healthy adult volunteers, together with FDA Fast Track designation for HHT and IND clearance for our Phase 1b trial, support our plans to evaluate TX2100 in patients with HHT.”
Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic
“We plan to initiate an open-label Phase 1b trial in patients with hematologic-support-dependent HHT by year-end 2026 and, in parallel, a placebo-controlled Phase 2 trial in patients with moderate-to-severe HHT in early 2027.”
Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic
“We are also approaching a critical milestone for TX45, with topline results from our APEX Phase 2 trial in PH-HFpEF anticipated by the end of January 2027.”
* Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adult volunteers; FDA granted TX2100 Fast Track designation for Hereditary Hemorrhagic Telangiectasia (“HHT”) in September 2026 and cleared the Investigational New Drug (“IND”) application in August 2026 for the planned Phase 1b clinical trial * Dosed first patient in the ALPINE Phase 2a clinical trial of TX45 in pulmonary hypertension associated with interstitial lung disease (“PH-ILD”) in October 2026, with interim topline results expected in the second half of 2027 * TERRA Phase 1b clinical trial of TX2100 in hematologic-support-dependent HHT expected to initiate by year-end 2026, with interim topline results expected by year-end 2027, and in parallel, the TIDAL Phase 2 clinical trial in moderate-to-severe HHT expected to initiate in early 2027 * Topline results from the APEX Phase 2 clinical trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) are anticipated by the end of January 2027 * Cash and cash equivalents of $234.7 million as of September 30, 2026, including approximately $22.3 million in net proceeds raised from an at-the-market offering for the three months ended September 30, 2026, is expected to provide cash runway into Q1 2029 WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the third quarter ended September 30, 2026, and provided an overview of recent business highlights.
Get started
Create a free account to read the full story.